CTNM Earnings — Contineum Therapeutics, Inc. Class A Common Stock Post-ER Performance | BigEarnings
CTNM — Contineum Therapeutics, Inc. Class A Common Stock
XNAS · Healthcare · Biotechnology
Price$13.49
Market Cap$504.3M
P/E—
52W Range$3.57 – $16.33
Next Earnings2026-08-04
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
